The DOI matches its Crossref record; 70 of the 74 references it cites were found in a registry or an index; 14 of the 43 sources its claims cite were checked for support.
Modulation of K-Ras-Dependent Lung Tumorigenesis by MicroRNA-21
Open accessAbstract
Lung cancer is the leading cause of cancer-related deaths in the world, and non-small-cell lung cancer (NSCLC) accounts for 80% of cases. MicroRNA-21 (miR-21) expression is increased and predicts poor survival in NSCLC. Although miR-21 function has been studied in vitro with cancer cell lines, the role of miR-21 in tumor development in vivo is unknown. We utilize transgenic mice with loss-of-function and gain-of-function miR-21 alleles combined with a model of NSCLC to determine the role of miR-21 in lung cancer. We show that overexpression of miR-21 enhances tumorigenesis and that genetic deletion of miR-21 partially protects against tumor formation. MiR-21 drives tumorigenesis through inhibition of negative regulators of the Ras/MEK/ERK pathway and inhibition of apoptosis.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
In a K-rasLA2 mouse model of NSCLC, miR-21 overexpression increased lung tumor number/area and proliferation, while miR-21 deletion reduced tumor burden and sensitized transformed MEFs to doxorubicin-induced apoptosis. miR-21 acts as a tumor promoter by repressing Ras/MEK/ERK negative regulators (Spry1, Spry2, Btg2, Pdcd4) and pro-apoptotic genes (Apaf1, Faslg, Pdcd4, RhoB).
Key findings
- CAG-miR-21;K-rasLA2 mice overexpressing miR-21 4–6 fold had significantly more gross lung tumors at 18 weeks and increased microscopic tumor number and total tumor area versus K-rasLA2 littermates; tumors showed increased proliferation, but survival did not differ, possibly due to decreased thymic tumor incidence.
- miR-21−/−;K-rasLA2 mice had significantly fewer surface lung tumors at 20 weeks and decreased total tumor area; no adenocarcinomas were noted in any of 14 miR-21−/−/K-rasLA2 animals evaluated, and miR-21 deletion did not alter Ki67 proliferation.
- miR-21 overexpression alone was not sufficient for tumorigenesis: CAG-miR-21 mice without K-rasLA2 (n = 39) followed up to 555 days showed no tumors.
- Reporter assays showed 13 of 24 putative mouse miR-21 target 3′UTRs were repressed by miR-21, with mutation of the miR-21 site abrogating repression in 11; in tumors, miR-21 overexpression decreased Spry1, Spry2, Btg2, Pdcd4, Apaf1, Faslg, and RhoB and increased ERK phosphorylation. K-ras activation increased miR-21 expression 4-fold; miR-21−/− MEFs formed fewer soft agar colonies and smaller xenograft tumors and showed increased doxorubicin-induced apoptosis.
Methods
- Generated conditional CAG-miR-21 overexpressing and miR-21−/− mice, crossed to the K-rasLA2 NSCLC model; comparisons were to littermate controls, with tumor burden assessed by H&E/ImageJ, proliferation by Ki67, and apoptosis by TUNEL.
- MEFs from wild-type and miR-21−/− mice were immortalized with SV40 large T/small t and transformed with H-rasG12V; assays included soft agar, xenografts, doxorubicin treatment (100 nM–10 μM for 12 h), and TUNEL (1 μM for 12 h).
- Luciferase reporter assays tested 24 putative miR-21 target 3′UTRs; Western blots were performed on micro-dissected tumors; statistics used two-tailed unpaired Student’s t-test with p < 0.05 considered significant.
Limitations
- No formal limitations section is present; the authors state miR-21 overexpression alone was not sufficient for tumorigenesis and that tumors arising after miR-21 deletion may have developed escape mechanisms, possibly explaining latency.
- The text notes miR-21 deletion did not alter apoptosis in lung lesions, suggesting those tumors escaped miR-21 regulatory effects; no adenocarcinomas were observed in 14 miR-21−/−;K-rasLA2 animals, a limited sample for that endpoint.
- Evident from the text: all mice used were of mixed genetic backgrounds, and findings are from a mouse K-rasLA2 model and transformed MEFs, so human NSCLC causality and therapeutic implications remain to be tested.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
14 of 43 cited sources checked · 6 supported · 0 flagged · accuracy not yet measured
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Four of the validated miR-21 target genes are known negative regulators of the Ras/MEK/ERK pathway: sprouty 1 (Spry1), sprouty 2 (Spry2), B-cell translocation gene 2 (Btg2), and programmed cell death 4 (Pdcd4).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 targets multiple tumor suppressor genes
What the sources say
- Partly supportedcites Casci et al., 1999 sourceExperimental — accuracy not yet measured
The Discussion identifies Drosophila Sprouty as an inhibitor of Ras/MAP kinase signaling. The paper predicts that mammalian Sprouty homologs may have the same function, but does not establish it for Spry1 or Spry2 specifically. It does not address Btg2, Pdcd4, or whether these genes are validated miR-21 targets. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites Hanafusa et al., 2002 source
- Not matchedcites Lo et al., 2006
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Oncogenic Ras activation has been shown to increase the expression of Spry2, providing feedback inhibition of Ras activation (Shaw et al., 2007).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > DISCUSSION
What the sources say
- Partly supportedcites Shaw et al., 2007 sourceExperimental — accuracy not yet measured
In “Negative feedback signaling in development” (page not available), the paper reports that oncogenic K-ras up-regulates Spry-2 and that Spry-2 inhibits MAPK activation. It does not establish that Spry-2 inhibits activation of Ras itself; it describes possible effects at different points in the Ras/MAPK pathway, including downstream of activated K-ras. (LLM, conf=0.86)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We show that over-expression of miR-21 enhances tumorigenesis and genetic deletion of miR-21 partially protects against tumor formation.”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We show that over-expression of miR-21 enhances tumorigenesis and genetic deletion of miR-21 partially protects against tumor formation.”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“K-ras activation in the tumors of K-rasLA2 mice increased miR-21 expression 4-fold similar to the expression level in the CAG-miR-21 transgenic mouse lung.”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > Oncogenic Ras activation increases miR-21 expression In vivo
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Total tumor area as a proportion of total lung area was significantly decreased with miR-21 deletion (Figure 2D).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 deletion suppresses tumor development In vivo
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“MiR-21 over-expression in CAG-miR-21;K-rasLA2 mutant tumors decreases Spry1, Spry2, and Btg2 protein expression compared to K-rasLA2 tumors (Figure 4C).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 targets multiple negative regulators of Ras signaling
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Rests on an assumption: The antibodies used in Western blots specifically detect the intended target proteins.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This is may be explained by a decreased incidence of thymic tumors in CAG-miR-21;K-rasLA2 mutant mice compared to K-rasLA2 controls (Figure 1I), thus contributing to the enhanced survival.”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 over-expression promotes tumor development In vivo
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There was no difference in proliferation between the miR-21−/− and wild type MEFs (Figure S2C).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 deletion suppresses Ras-driven transformation In vitro
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Total tumor area as a proportion of total lung area was significantly increased with miR-21 over-expression (Figure 1E).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 over-expression promotes tumor development In vivo
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes
- Probably not a substantial claim. 25
- It may state two separate claims as one. 35
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Recently, miR-21 expression levels have proven useful prognostic markers in non-small cell lung cancer (Markou et al., 2008; Yanaihara et al., 2006).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > INTRODUCTION
What the sources say
- Supportedcites Markou et al., 2008 source
The discussion reports that mature miR-21 overexpression in NSCLC was associated with lung-cancer death and was an independent prognostic factor in multivariate analysis. The authors caution that the small number of events requires further confirmation, so the finding should not be read as a validated clinical test. (LLM, conf=0.88)
- Partly supportedcites Yanaihara et al., 2006 sourceExperimental — accuracy not yet measured
The Results report that high hsa-mir-21 expression was associated with significantly worse survival in lung adenocarcinoma patients. They do not establish miR-21 as a validated prognostic marker across non-small cell lung cancer: the reported prognostic validation focused on other miRNAs. (LLM, conf=0.88)
Strength:boosted· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The level of miR-21 expression in sputum distinguishes NSCLC patients from cancer-free controls with a greater sensitivity than conventional cytology (Xie et al., 2009).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > INTRODUCTION
What the sources say
- Supportedcites Xie et al., 2009 source
The Results section, under “Comparison of cytology and measurement of altered miRNA expression in sputum,” reports 69.66% sensitivity for sputum miR-21 measurement versus 47.82% for conventional sputum cytology. The study examined sputum from 23 NSCLC patients and 17 cancer-free subjects, matching the claimed comparison. (LLM, conf=0.95)
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Several components of the PI3K pathway, including PTEN and PIK3R1, have been suggested as miR-21 target genes (Meng et al., 2007); however, miR-21 over-expression did not alter PTEN and PIK3R1 protein expression or Akt phosphorylation (Figure S3B).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 targets multiple negative regulators of Ras signaling
What the sources say
- Partly supportedcites Meng et al., 2007 sourceExperimental — accuracy not yet measured
The Results identify PTEN as a miR-21 target, and the Discussion places PTEN in the PI3K pathway. The passages do not identify PIK3R1 as a miR-21 target. The statement that over-expression did not alter protein expression or Akt phosphorylation is attributed to the citing paper’s Figure S3B, not to Meng et al. (LLM, conf=0.87)
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The antibodies used in Western blots specifically detect the intended target proteins.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Targeted deletion of miR-21 in RKO and DLD1 colon cancer cells revealed miR-21 contributes to tumorigenesis through compromising cell cycle progression and DNA damage-induced checkpoint function through the Cdc25a target gene (Wang et al., 2009).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > INTRODUCTION
What the sources say
- Partly supportedcites Wang et al., 2009 sourceExperimental — accuracy not yet measured
The Results report targeted miR-21 deletion in RKO and DLD1 cells, and the Discussion links miR-21, Cdc25A, cell-cycle progression, and checkpoint activation. However, the Discussion describes a contribution to tumorigenesis as a possibility, not a demonstrated outcome; the claim's “revealed” overstates that conclusion. (LLM, conf=0.88)
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“As well, epidermal growth factor receptor (EGFR) and HER2/neu signaling positively regulates miR-21 expression in human lung and breast carcinoma cell lines, respectively (Huang et al., 2009; Seike et al., 2009).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > Oncogenic Ras activation increases miR-21 expression In vivo
What the sources say
- Supportedcites Huang et al., 2009 source
The paired citations and “respectively” attribute the HER2/neu finding in breast carcinoma cells to Huang et al. In “Ectopic Expression of HER2/neu Induces miR-21 Upregulation” (Fig. 1A; page not provided), the paper reports that HER2/neu expression increased miR-21 in a human breast cancer cell line. The EGFR finding in lung cells is not attributed to this source. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites Seike et al., 2009 source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Zhang et al. showed in a human gastric cancer cell line that forced over-expression of miR-21 enhanced tumor proliferation and invasion”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > DISCUSSION
What the sources say
- Supportedcites Zhang et al., 2008 source
In the Results sections on proliferation and invasion (page numbers not provided), the paper reports that transfecting AGS human gastric cancer cells with a miR-21 expression construct significantly increased proliferation and strengthened invasion. This matches the claim about forced over-expression in a human gastric cancer cell line. (LLM, conf=0.94)
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“SPRY2, in turn, negatively regulates Ras/MEK/ERK signaling and is a tumor suppressor in NSCLC in both mice (Minowada and Miller, 2004; Minowada and Miller, 2009; Shaw et al., 2007) and humans (Sutterluty et al., 2007).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites Minowada and Miller, 2004 source
- Partly supportedcites Minowada and Miller, 2009 sourceExperimental — accuracy not yet measured
The study summary and Discussion (page unavailable) report fewer and smaller urethane-induced lung tumors in mice overexpressing Sprouty 2, supporting a tumor-suppressive effect in that mouse model. The Discussion says the findings are consistent with antagonism of Ras signaling, but the mechanism remains unclear; this paper does not demonstrate inhibition of MEK/ERK signaling. The citing sentence attributes the human NSCLC portion to a separate citation, not to this paper. (LLM, conf=0.83)
- Supportedcites Shaw et al., 2007 source
The Negative feedback signaling in development section reports that Spry-2 inhibits MAPK activation in K-ras G12D mouse lungs. The tumor-suppression section concludes that Spry-2 limits K-ras-driven mouse lung tumor development; a correction in Additional information says its revised results do not change that conclusion. The citing sentence attributes the human finding to Sutterluty et al., not to this paper. (LLM, conf=0.90)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“All tumors from the survival cohort were analyzed on H&E sections and categorized as hyperplasia, atypical adenomatous hyperplasia, adenoma, adenoma with typia, and adenocarcinoma according to the Mouse Models of Human Cancer Consortium recommendations.(Nikitin et al., 2004)”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > EXPERIMENTAL PROCEDURES > Tumor Grading
What the sources say
- Partly supportedcites Nikitin et al., 2004 sourceExperimental — accuracy not yet measured
The Development of Recommendations section says the consortium prepared and reviewed H&E-stained sections, and the classification defines hyperplasia, atypical adenomatous hyperplasia, adenoma, and adenocarcinoma. The cited paper does not identify “adenoma with typia” as a recommended category. The survival-cohort analysis describes the citing authors’ own work, not an analysis reported by Nikitin et al. (LLM, conf=0.85)
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“knock-down of miR-21 resulted in a marked reduction in proliferation and increase in apoptosis (Zhang et al., 2008).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > DISCUSSION
What the sources say
- Supportedcites Zhang et al., 2008 source
The Abstract states that inhibiting miR-21 in AGS human gastric cancer cells significantly reduced proliferation and increased apoptosis. The ‘miR-21 Increases Cell Proliferation and Inhibits Cell Apoptosis’ section reports both effects after transfection with an anti-miR-21 inhibitor. (LLM, conf=0.95)
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Methods have been developed to manipulate miRNA function pharmacologically, facilitating the development of new cancer therapeutic strategies (Hutvagner et al., 2004; Krutzfeldt et al., 2005).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > DISCUSSION
What the sources say
- Partly supportedcites Hutvagner et al., 2004 sourceExperimental — accuracy not yet measured
The Results and Discussion report that 2′-O-methyl oligonucleotides inhibit specific miRNAs and can be used to study their function in C. elegans. The paper presents them as a research tool; it does not establish that they facilitate new cancer therapeutic strategies. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites Krutzfeldt et al., 2005 source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“RECK, Cdc25a, Map2k3, NfiB, Trp63 and Ski have been shown to be miR-21 target genes in vitro, but only RECK showed decreased protein levels in the CAG-miR-21;K-rasLA2 tumors (Figure S3A).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 targets multiple negative regulators of Ras signaling
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The antibodies used in Western blots specifically detect the intended target proteins.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“MiR21−/−;K-rasLA2 mice all develop lung tumors, but show an increased incidence of thymic lymphoma (Figure 2F).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 deletion suppresses tumor development In vivo
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Caspase 3 and K-ras do not contain miR-21 sites in their 3′ UTR and the 3′ UTR luciferase reporter activity is not suppressed by miR-21 (Figure 3B).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 targets multiple tumor suppressor genes
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The decrease in Spry1, Spry2, and Btg2 in CAG-miR-21;K-rasLA2 tumors correlates with increased Ras pathway activity, shown by increased ERK phosphorylation (Figure 4C).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 targets multiple negative regulators of Ras signaling
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The antibodies used in Western blots specifically detect the intended target proteins.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We show miR-21 dependent repression of the mouse Apaf1 3′ UTR reporter; however, the miR-21 site in the human APAF1 3′ UTR is conserved in primates but not conserved in the mouse.”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 targets multiple tumor suppressor genes
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“adult male CAG-miR-21 mice showed no signs of heart failure compared to littermate controls (Figure S1E)(van Rooij et al., 2006; van Rooij et al., 2008).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 over-expression promotes tumor development In vivo
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Apaf1, Pdcd4, Faslg, and RhoB were validated as direct miR-21 target genes by luciferase reporter assays; however, caspase 3 was not directly regulated by miR-21 (Figure 3B).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 suppresses apoptosis by targeting proapoptotic genes
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The luciferase reporter assays in COS cells reflect endogenous miR-21 target regulation in mouse lung tumors.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“MiR-21 over-expression increased the incidence of all tumor grades without increasing the rate of conversion to adenocarcinoma, suggesting that miR-21 participates in tumor promotion rather than progression and metastasis in this model (Figure 1J and 1K).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 over-expression promotes tumor development In vivo
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Unlike K-rasLA1;p53−/− compound mutant mice (Johnson et al., 2001), we did not observe an increased tumor spectrum or increased metastasis in the CAG-miR-21;K-rasLA2 mutant mice.”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 over-expression promotes tumor development In vivo
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Although miR-21 function has been studied in vitro using cancer cell lines, the role of miR-21 in tumor development in vivo is unknown.”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > Abstract
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“MiR-21 drives tumorigenesis through inhibition of negative regulators of the Ras/MEK/ERK pathway and inhibition of apoptosis.”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“A large scale survey to determine the miRNA signature of 540 tumor samples including lung, breast, stomach, prostate, colon, and pancreatic tumors and their respective normal adjacent tissue revealed miR-21 was the only miRNA up-regulated in all these tumors (Volinia et al., 2006).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > INTRODUCTION
What the sources say
- Not checked — no full text of the sourcecites Volinia et al., 2006 source
Tests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“Further miRNA profiling in tumor samples and cancer cell lines show increased miR-21 expression in glioblastoma (Chan et al., 2005; Ciafre et al., 2005), head and neck carcinomas (Tran et al., 2007), ovarian cancer (Iorio et al., 2007), B-cell lymphoma (Lawrie et al., 2007), hepatocellular (Meng et al., 2007), and cervical carcinoma (Lui et al., 2007).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > INTRODUCTION
What the sources say
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“CAG-miR-21 transgenic mice were viable, fertile and born in expected Mendelian ratios.”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 over-expression promotes tumor development In vivo
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Knock-down of miR-21 in the metastatic breast cancer MD-MBA-231 cells reduced invasion and metastasis (Zhu et al., 2008).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > INTRODUCTION
What the sources say
- Not checked — no full text of the sourcecites Zhu et al., 2008 source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Homozygous miR-21 knock-out mice are viable, fertile, and born in expected Mendelian ratios without any gross phenotypic differences compared to wild type or heterozygous littermates, and without a cardiac phenotype (D.P., E.V.R. and E.N.O., manuscript in preparation).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 deletion suppresses Ras-driven transformation In vitro
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
- Rests on an assumption: The miR-21 knockout mice do not have compensatory molecular changes that confound the interpretation of tumorigenesis experiments.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These data illustrate that miR-21 over-expression decreases the protein expression of four miR-21 target genes that are involved in apoptosis thus promoting survival.”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 suppresses apoptosis by targeting proapoptotic genes
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The antibodies used in Western blots specifically detect the intended target proteins.
- Rests on an assumption: The luciferase reporter assays in COS cells reflect endogenous miR-21 target regulation in mouse lung tumors.
In the paper
“miR-21 expression was induced by AP-1 in response to Ras activation, and miR-21 mediated Ras-dependent downregulation of Pdcd4 (Talotta et al., 2009)”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > Oncogenic Ras activation increases miR-21 expression In vivo
What the sources say
- Not checked — no full text of the sourcecites Talotta et al., 2009 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may state two separate claims as one.
In the paper
“Knockdown of miR-21 in cultured glioblastoma cells activates caspases leading to apoptotic cell death, suggesting miR-21 is an anti-apoptotic factor (Chan et al., 2005).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > INTRODUCTION
What the sources say
- Not checked — no full text of the sourcecites Chan et al., 2005 source
Strength:hedged· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“K-rasLA2 mice develop multi-focal lung tumors with 100% penetrance, and less frequently develop thymic lymphomas and skin papillomas (Johnson et al., 2001).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 over-expression promotes tumor development In vivo
What the sources say
- Not checked — no full text of the sourcecites Johnson et al., 2001 source
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These data suggest that miR-21 over-expression in human tumors does not simply reflect cancer pathology, but instead enhances aspects of the pathology of NSCLC.”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 over-expression promotes tumor development In vivo
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The K-rasLA2 mouse model is a valid model of human NSCLC for studying miR-21.
- Rests on an assumption: The level of miR-21 over-expression achieved in CAG-miR-21 mice (4–6 fold) is representative of the increased miR-21 expression in human NSCLC.
In the paper
“Previously, an autoregulatory loop connecting miR-21 and Ras activation through AP-1 was illustrated in a rat thyroid cell system (Talotta et al., 2009).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > Oncogenic Ras activation increases miR-21 expression In vivo
What the sources say
- Not checked — no full text of the sourcecites Talotta et al., 2009 source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These data show that miR-21 over-expression decreases the protein expression of four miR-21 target genes that are tumor suppressors and negative regulators of the Ras/MEK/ERK pathway resulting in a concomitant increased ERK activity.”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 targets multiple negative regulators of Ras signaling
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The antibodies used in Western blots specifically detect the intended target proteins.
- Rests on an assumption: The luciferase reporter assays in COS cells reflect endogenous miR-21 target regulation in mouse lung tumors.
In the paper
“In breast cancer MCF-7 cells, miR-21 knock-down results in suppression of cell growth in vitro and tumor growth in xenografts (Si et al., 2007).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > INTRODUCTION
What the sources say
- Not matchedcites Si et al., 2007
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
- Not matched
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“All mice used in these studies were of mixed genetic backgrounds and all comparisons were performed on littermate controls.”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > EXPERIMENTAL PROCEDURES > Mouse Strains
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“PDCD4 is a pro-apoptotic tumor suppressor gene and has been verified as a miR-21 target in human colorectal and breast cancer cell lines (Afonja et al., 2004; Asangani et al., 2007; Bitomsky et al., 2008; Frankel et al., 2007; Lu et al., 2008; Zhang et al., 2006).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > DISCUSSION
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“In laryngeal carcinoma, miR-21 targets BTG2 (Liu et al., 2009), a p53 target gene, recently shown to suppress oncogenic Ras activity by reducing the GTP bound, active state (Buganim et al., 2010).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > DISCUSSION
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Knock-down of miR-21 in glioblastoma cell lines triggers the activation of caspases and increases apoptosis (Chan et al., 2005).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites Chan et al., 2005 source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“RhoB promotes growth inhibition and induces apoptosis in cancer cells (Kim et al., 2009)”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites Kim et al., 2009 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Although the reductions in protein levels of individual miR-21 targets appear modest with miR-21 over-expression, collectively this diminution of tumor suppressor activity allows for more robust tumor formation through relieving multiple nodes of inhibition of the Ras/MEK/ERK pathway, thus facilitating tumor proliferation.”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > DISCUSSION
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The K-rasLA2 mouse model is a valid model of human NSCLC for studying miR-21.
- Rests on an assumption: The antibodies used in Western blots specifically detect the intended target proteins.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We show that Ras activation increases miR-21 expression and in turn decreasing the expression of Spry2.”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > DISCUSSION
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The K-rasLA2 mouse model is a valid model of human NSCLC for studying miR-21.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“miR-21 modulates several components critical to NSCLC pathogenesis through both relieving antagonism of the Ras pathway and reducing apoptotic effectors (Figure 7).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > DISCUSSION
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The K-rasLA2 mouse model is a valid model of human NSCLC for studying miR-21.
In the paper
“RhoB expression is down-regulated in human NSCLC suggesting a role as a tumor suppressor gene (Sato et al., 2007).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites Sato et al., 2007 source
Strength:hedged· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Relieving miR-21 inhibition of pro-apoptotic genes could provide a means to augment the effect of current chemotherapy.”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > DISCUSSION
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
- Rests on an assumption: Apaf1, Faslg, Pdcd4 and RhoB promote apoptosis.
In the paper
“MiR-21 targets SPRY2 in cardiomyocytes and SW480 colon cancer cells, enhancing cell migration (Sayed et al., 2008).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites Sayed et al., 2008 source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Our results show that miR-21 expression modulates tumor number, incidence and size in a mouse lung cancer model initiated by oncogenic K-rasG12D, consistent with miR-21 functioning as a tumor promoter.”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > DISCUSSION
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The K-rasLA2 mouse model is a valid model of human NSCLC for studying miR-21.
- Rests on an assumption: The level of miR-21 over-expression achieved in CAG-miR-21 mice (4–6 fold) is representative of the increased miR-21 expression in human NSCLC.
In the paper
“Pdcd4 functions both as an inducer of apoptosis and a suppressor of AP-1 activity (Hwang et al., 2007).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites Hwang et al., 2007 source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“Loss of PDCD4 expression in human lung cancer correlates with higher grade and disease stage (Chen et al., 2003).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites Chen et al., 2003 source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
The paper relies on this without support.
The K-rasLA2 mouse model is a valid model of human NSCLC for studying miR-21.
“To explore the role of miR-21 in the pathogenesis of NSCLC, we utilized the K-rasLA2 murine lung cancer model, which harbors a targeted, latent K-ras G12D allele that is activated by two distinct recombination events (Johnson et al., 2001).”
The paper relies on this without support.
The level of miR-21 over-expression achieved in CAG-miR-21 mice (4–6 fold) is representative of the increased miR-21 expression in human NSCLC.
“which globally over-expressed miR-21 4–6 fold over normal levels of expression (Figure S1B–D).”
The paper relies on this without support.
The miR-21 knockout mice do not have compensatory molecular changes that confound the interpretation of tumorigenesis experiments.
“Homozygous miR-21 knock-out mice are viable, fertile, and born in expected Mendelian ratios without any gross phenotypic differences compared to wild type or heterozygous littermates, and without a cardiac phenotype (D.P., E.V.R. and E.N.O., manuscript in preparation).”
The paper relies on this without support.
The antibodies used in Western blots specifically detect the intended target proteins.
“We isolated individual tumors from mice, made whole tumor lysates, and performed Western blots for putative miR-21 targets to address the effect of miR-21 expression on the protein levels of the miR-21 target genes in vivo within lung tumors.”
The paper relies on this without support.
The luciferase reporter assays in COS cells reflect endogenous miR-21 target regulation in mouse lung tumors.
“Reporter assays in COS cells revealed miR-21 dependent repression of 13 of the 24 3′UTRs”
The paper relies on this without support.
MicroRNAs are small non-coding RNAs that are commonly dysregulated in human malignancies and play a substantial role in the pathogenesis and survival of many cancers.
“MicroRNAs are small non-coding RNAs that are commonly dysregulated in human malignancies and play a substantial role in the pathogenesis and survival of many cancers.”
The paper relies on this without support.
MiR-21 is over-expressed in the majority of human malignancies including non-small cell lung cancer (NSCLC).
“MiR-21 is over-expressed in the majority of human malignancies including non-small cell lung cancer (NSCLC).”
The paper relies on this without support.
It is not clear whether miR-21 determines important aspects of lung cancer pathogenesis or is instead simply a marker for advanced disease.
“However, it is not clear whether miR-21 determines important aspects of lung cancer pathogenesis or is instead simply a marker for advanced disease.”
The paper relies on this without support.
Spry1, Spry2, Btg2, and Pdcd4 act as negative regulators of the Ras/MEK/ERK pathway.
“which act as negative regulators of the Ras/MEK/ERK pathway”
The paper relies on this without support.
Apaf1, Faslg, Pdcd4 and RhoB promote apoptosis.
“which promote apoptosis”
Citations
Cites
Bartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714
Lewis, B. P., Burge, C. B., & Bartel, D. P. (2005) · Cell · doi:10.1016/j.cell.2004.12.035 · Cited by 11,855 · cited 2×
“Expression of approximately 30% of human proteins appears to be regulated by miRNAs (Lewis et al., 2005).”
MicroRNA signatures in human cancers
Calin, G. A., & Croce, C. M. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1997 · Cited by 7,668 · cited 2×
“…including non-small-cell lung cancer (NSCLC) (Volinia et al., 2006), and are predictive of tumor classification, prognosis, and response to therapy (Calin and Croce, 2006). miRNA expression patterns are remarkably reliable markers of cancers; in some cases, they have even proven more reliable than…”
Oncomirs—MicroRNAs with a role in cancer
Esquela-Kerscher, A., & Slack, F. J. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1840 · Cited by 5,884 · cited 4×
“MicroRNAs are evolutionarily conserved, endogenous, nonprotein-coding, 20–23 nucleotide single-stranded RNAs that negatively regulate gene expression in a sequence-specific manner (Cho, 2007; Esquela-Kerscher and Slack, 2006; Voorhoeve and Agami, 2007).”
InfluentialA microRNA expression signature of human solid tumors defines cancer gene targets
Volinia, S., Calin, G. A., Liu, C.-G., Ambs, S., Cimmino, A., Petrocca, F., Visone, R., Iorio, M., Roldo, C., Ferracin, M., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510565103 · Cited by 5,697 · cited 4×
“A large-scale survey to determine the miRNA signature of 540 tumor samples—including lung, breast, stomach, prostate, colon, and pancreatic tumors and their respective normal adjacent tissue—revealed miR-21 was the only miRNA upregulated in all these tumors (Volinia et al., 2006).”
InfluentialCombinatorial microRNA target predictions
Krek, A., Grün, D., Poy, M. N., Wolf, R., Rosenberg, L., Epstein, E. J., MacMenamin, P., da Piedade, I., Gunsalus, K. C., Stoffel, M., et al. (2005) · Nature Genetics · doi:10.1038/ng1536 · Cited by 4,603 · cited 2×
“, 2007), and PicTar (Krek et al., 2005).”
Silencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949 · cited 2×
“Methods have been developed to manipulate miRNA function pharmacologically, facilitating the development of new cancer therapeutic strategies (Hutvagner et al., 2004; Krutzfeldt et al., 2005).”
MicroRNA Targeting Specificity in Mammals: Determinants beyond Seed Pairing
Grimson, A., Farh, K. K.-H., Johnston, W. K., Garrett-Engele, P., Lim, L. P., & Bartel, D. P. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.06.017 · Cited by 3,766 · cited 2×
“Can miR-21 Targets Multiple Tumor Suppressor Genes To identify miR-21 effectors responsible for phenotypes observed, we utilized two algorithms that predict the mRNA targets of miRNAs, TargetScan (Grimson et al., 2007), and PicTar (Krek et al.”
The impact of microRNAs on protein output
Baek, D., Villén, J., Shin, C., Camargo, F. D., Gygi, S. P., & Bartel, D. P. (2008) · Nature · doi:10.1038/nature07242 · Cited by 3,592 · cited 2×
“Through interactions with 30 UTRs, miRNAs can modulate the expression of many genes simultaneously, often regulating individual signaling pathways at multiple levels (Baek et al., 2008; Selbach et al., 2008).”
Widespread changes in protein synthesis induced by microRNAs
Selbach, M., Schwanhäusser, B., Thierfelder, N., Fang, Z., Khanin, R., & Rajewsky, N. (2008) · Nature · doi:10.1038/nature07228 · Cited by 3,429 · cited 2×
“Through interactions with 30 UTRs, miRNAs can modulate the expression of many genes simultaneously, often regulating individual signaling pathways at multiple levels (Baek et al., 2008; Selbach et al., 2008).”
Flagged first, then by citations
4 of the 74 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 201–300 of 625
Zheng, Q., Peskoe, S. B., Ribas, J., Rafiqi, F. H., Kudrolli, T. A., Meeker, A. K., Marzo, A. M. D., Platz, E. A., & Lupold, S. E. (2014) · The Prostate · doi:10.1002/pros.22883 · Cited by 59
“This was a surprising result because miR-21 has been shown to have oncogenic, growth and survival promoting properties in prostate and other cancer models [40,42-48].”
BackgroundKrissansen, G. W., Yang, Y., McQueen, F. M., Leung, E. Y., Peek, D., Chan, Y. C., Print, C. G., Dalbeth, N., Williams, M. J., & Fraser, A. G. (2015) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000285 · Cited by 59
Expression of miR-148/152 Family as Potential Biomarkers in Non-Small-Cell Lung Cancer
Qin, Y. (2015) · Medical Science Monitor · doi:10.12659/msm.892940 · Cited by 58
Akagi, I., Okayama, H., Schetter, A. J., Robles, A. I., Kohno, T., Bowman, E. D., Kazandjian, D. G., Welsh, J. A., Oue, N., Saito, M., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0031 · Cited by 58
“In a mouse model of NSCLC, miR-21 overexpression enhanced tumorigenesis and its deletion reduced it, providing a direct link between miR-21 and lung carcinogenesis (50).”
BackgroundStromal Expression of miR-21 Identifies High-Risk Group in Triple-Negative Breast Cancer
MacKenzie, T. A., Schwartz, G. N., Calderone, H. M., Graveel, C. R., Winn, M. E., Hostetter, G. H., Wells, W. A., & Sempere, L. F. (2014) · American Journal Of Pathology · doi:10.1016/j.ajpath.2014.08.020 · Cited by 60
AC1MMYR2 impairs high dose paclitaxel-induced tumor metastasis by targeting miR-21/CDK5 axis
Ren, Y., Zhou, X., Yang, J.-J., Liu, X., Zhao, X., Wang, Q.-X., Han, L., Song, X., Zhu, Z.-Y., Tian, W.-P., et al. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.03.038 · Cited by 59
Mi, L., Chen, Y., Zheng, X., et al. (2014) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25065 · Cited by 57
“, 2005), tumorigenesis (Kumar et al., 2007; Hatley et al., 2010), and neuronal development (Fiore et al.”
BackgroundmiRNA and lncRNA as biomarkers in cholangiocarcinoma(CCA)
Zheng, B. J., Jeong, S., Zhu, Y., Chen, L., & Xia, Q. (2017) · Oncotarget · doi:10.18632/oncotarget.19044 · Cited by 57
“Some miRNAs like miR-21 [27, 28], miR-155 [29, 30] and miR17-92 cluster are recognized as tumor promoter [31, 32], some as tumor suppressors [33].”
BackgroundPrognostic, therapeutic and diagnostic potential of microRNAs in non-small cell lung cancer
Markou, A. N., Liang, Y., & Lianidou, E. S. (2011) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2011.661 · Cited by 58
“Finally, miR-21 drives tumorigenesis through inhibition of negative regulators of the RAS/MEK/ERK pathway and inhibition of apoptosis (65).”
BackgroundControl of microRNA biogenesis and transcription by cell signaling pathways
Saj, A., & Lai, E. C. (2011) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2011.04.010 · Cited by 58
“The expression of miR-21 was earlier shown to be universally elevated in hundreds of human solid tumors across a panel of tissue origins [63], and a variety of tests in cancer cell lines suggested it to have oncogenic activity, since it represses a number of tumor suppressor genes [62 ,64], inhibits apoptosis, and can…”
BackgroundThe Duality of OncomiR Addiction in the Maintenance and Treatment of Cancer
Cheng, C. J., & Slack, F. J. (2012) · The Cancer Journal · doi:10.1097/ppo.0b013e318258b75b · Cited by 57
Othman, N., & Nagoor, N. H. (2014) · BioMed Research International · doi:10.1155/2014/318030 · Cited by 57
“miR-21 SPRY1, SPRY2, BTG2, PDCD4, APAF1, FasL, RHOB Enhance tumor proliferation and survival Inhibit apoptosis miR deletion suppresses Ras-driven transformation N/T K-ras LA2 mice CAG-miR-21 transgenic mice CAG-miR-21;K-ras LA2 compound mutant mice [37]”
BackgroundInfluentialThe Pattern of microRNA Binding Site Distribution
Zhang, F., & Wang, D. (2017) · Genes · doi:10.3390/genes8110296 · Cited by 56
Gastric adenocarcinoma has a unique microRNA signature not present in esophageal adenocarcinoma
Chen, Z., Saad, R., Jia, P., Peng, D., Zhu, S., Washington, M. K., Zhao, Z., Xu, Z., & El-Rifai, W. M. (2013) · Cancer · doi:10.1002/cncr.28002 · Cited by 57
“Recent studies have demonstrated several oncogenic functions for miR-21, indicating its role in inhibiting apoptosis by suppressing the inhibitors of Ras/MEK/ ERK.(36) It has also been demonstrated that miR-21 overexpression mediates the activation of NF-jB signaling, providing a link between inflammation and cancer.”
BackgroundMullenbrock, S., Shah, J., & Cooper, G. M. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.274076 · Cited by 57
microRNAs as pharmacological targets in cancer
Soriano, A., Jubierre, L., Almazán-Moga, A., Molist, C., Roma, J. M., de Toledo, J. S., Gallego, S., & Segura, M. F. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2013.03.006 · Cited by 58
Targeted Ablation of miR-21 Decreases Murine Eosinophil Progenitor Cell Growth
Lu, T. X., Lim, E. J., Itskovich, S. S., Besse, J. A., Plassard, A. J., Mingler, M. K., Rothenberg, J. A., Fulkerson, P. C., Aronow, B. J., & Rothenberg, M. E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059397 · Cited by 58
“MiR-21 has been known to promote cell growth in various cell types, most notable in tumor cells by targeting a variety of proapoptotic genes both directly and indirectly [20,21].”
Ma, Y., Xia, H., Liu, Y., et al. (2014) · BioMed Research International · doi:10.1155/2014/617868 · Cited by 56
“Furthermore, miR-21 is reported to be an antiapoptotic factor in lung cancer [32, 33].”
BackgroundMontalban, E., Mattugini, N., Ciarapica, R., Provenzano, C., Savino, M., Scagnoli, F., Prosperini, G., Carissimi, C., Fulci, V., Matrone, C., et al. (2014) · NeuroMolecular Medicine · doi:10.1007/s12017-014-8292-z · Cited by 56
Rolfo, C. D., Fanale, D., Hong, D. S., Tsimberidou, A. M., Piha-Paul, S. A., Pauwels, P., van Meerbeeck, J. P., Caruso, S., Bazan, V., Cicero, G., et al. (2014) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201015666140519123219 · Cited by 56
“For example, miR-21 is overexpressed in various cancers, including NSCLC, and acts as oncomiR by targeting genes related to proliferation, cell death, and invasion such as Apaf1, Faslg and RhoB, that are involved in the intrinsic/extrinsic apoptotic pathways [31].”
BackgroundTherapeutic Use of MicroRNAs in Lung Cancer
Fortunato, O., Boeri, M., Verri, C., Moro, M., & Sozzi, G. (2014) · BioMed Research International · doi:10.1155/2014/756975 · Cited by 56
“The role ofmir-21 as an oncogenicmiRNAand its therapeutic value were also demonstrated in an in vivo assay using K-rasLA2murinemodel of multifocal lung cancer, where the downmodulation ofmir-21 expression resulted in a reduction of tumor number, incidence, and size [55].”
BackgroundThe role of noncoding RNAs in epithelial cancer
Agostini, M., Ganini, C., Candi, E., & Melino, G. (2020) · Cell Death Discovery · doi:10.1038/s41420-020-0247-6 · Cited by 56
Röhr, C., Kerick, M., Fischer, A., Kühn, A., Kashofer, K., Timmermann, B., Daskalaki, A., Meinel, T., Drichel, D., Börno, S. T., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067461 · Cited by 55
“in ulcerative colitis, thus linking inflammation and cancer [10,11].”
BackgroundBinary System for MicroRNA-Targeted Imaging in Single Cells and Photothermal Cancer Therapy
Qian, R., Cao, Y. Z., & Long, Y. (2016) · Analytical Chemistry · doi:10.1021/acs.analchem.6b01804 · Cited by 55
Serum MicroRNA-21 as a Biomarker for Allergic Inflammatory Disease in Children
Sawant, D. V., Yao, W., Wright, Z., Sawyers, C. L., Tepper, R. S., Gupta, S. K., Kaplan, M. H., & Dent, A. L. (2015) · MicroRNA · doi:10.2174/2211536604666150220232507 · Cited by 54
MicroRNA Profiling in Lung Cancer Reveals New Molecular Markers for Diagnosis
Solomides, C., Evans, B. J., Navenot, J.-M., et al. (2012) · Acta Cytologica · doi:10.1159/000343473 · Cited by 54
Sharma, S. B., Lin, C., Farrugia, M. K., McLaughlin, S. L., Ellis, E. J., Brundage, K. M., Salkeni, M. A., & Ruppert, J. M. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.00480-14 · Cited by 54
Tumor diagnosis using carbon-based quantum dots: Detection based on the hallmarks of cancer
Wang, H., Yang, S., Chen, L., Li, Y., He, P., Wang, G., Dong, H., Ma, P., & Ding, G. (2023) · Bioactive Materials · doi:10.1016/j.bioactmat.2023.10.004 · Cited by 55
“MiRNAs are short, single-stranded RNA molecules [300 – 307] whose dysregulated expression is associated with various tumors: the miRNAs associated with some of the most common tumors are listed in Fig.”
BackgroundZhao, Y., Liu, H., Li, Y., et al. (2011) · Toxicology Letters · doi:10.1016/j.toxlet.2011.06.022 · Cited by 53
Peng, Y., Gao, Z., Qiao, B., Li, D., Pang, H., Lai, X., Pu, Q., Zhang, R., Zhao, X., Zhao, G., et al. (2023) · Advanced Science · doi:10.1002/advs.202300614 · Cited by 52
Zhao, Y., Schetter, A. J., Yang, G. B., Nguyen, G. H., Mathé, E. A., Li, P., Cai, H., Yu, L., Liu, F., Hang, D., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.27954 · Cited by 52
“Increased expression of miR-21 in the absence of other genetic defects is sufficient at causing malignancies in mice,(27) whereas deletion of miR-21 reduces KRAS-driven oncogenic transformation.(28) miR-21 Figure 3.”
BackgroundMicroRNAs and lung cancers: from pathogenesis to clinical implications
Qi, J., & Mu, D. (2012) · Frontiers of Medicine · doi:10.1007/s11684-012-0188-4 · Cited by 52
“clearly demonstrated the oncogenicity of miR-21 in lung cancers [38].”
BackgroundRegulation of T lymphocyte activation by microRNA-21
Wang, L., He, L., Zhang, R., Liu, X., Ren, Y., Liu, Z., Zhang, X., Cheng, W., & Hua, Z.-C. (2014) · Molecular Immunology · doi:10.1016/j.molimm.2014.02.004 · Cited by 52
Chen, H.-H., Huang, W., Yang, L., & Lin, C. (2015) · American Journal Of Pathology · doi:10.1016/j.ajpath.2015.01.025 · Cited by 52
The anti-tumorigenic activity of A2M—A lesson from the naked mole-rat
Kurz, S., Thieme, R., Amberg, R., Groth, M., Jahnke, H., Pieroh, P., Horn, L., Kolb, M., Huse, K., Platzer, M., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0189514 · Cited by 51
miRNAs as biomarkers and for the early detection of non-small cell lung cancer (NSCLC)
Han, Y., & Li, H. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.05.32 · Cited by 52
“MiR-21 promotes tumorigenesis through inhibition of regulators of the Ras/MEK/ERK pathway and blockage of apoptosis (58).”
BackgroundCancer stem cells: a challenging paradigm for designing targeted drug therapies
Khan, I. N., Alkarim, S., Bora, R. S., Chaudhary, A., & Saini, K. S. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.06.013 · Cited by 51
Therapeutic resistance in cancer: microRNA regulation of EGFR signaling networks.
Gomez, G. G., Wykosky, J., Zanca, C., Furnari, F. B., & Cavenee, W. K. (2013) · Europe PMC (PubMed Central) · doi:10.7497/j.issn.2095-3941.2013.04.003 · Cited by 53
Bera, A., Das, F., Ghosh‐Choudhury, N., Kasinath, B. S., Abboud, H. E., & Choudhury, G. G. (2014) · Experimental Cell Research · doi:10.1016/j.yexcr.2014.06.022 · Cited by 54
“In fact, mice overexpressing miR-21 show increased lung tumorigenesis while ablation of this overexpression protects against tumor formation [78].”
BackgroundTian, P., & Li, Y. (2016) · Medical Science Monitor · doi:10.12659/msm.899114 · Cited by 51
“To date, several miRNAs, such as miR-21 [24], miR-23a [25], and miR-25 [26], have shown the ability to target FASLG in different cancers.”
BackgroundYin, J., Zhao, J., Hu, W., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0172787 · Cited by 51
Plasmon-enhanced biosensors for microRNA analysis and cancer diagnosis
Lu, X., Yao, C., Sun, L., et al. (2022) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2022.114041 · Cited by 51
Androsavich, J. R., Chau, B. N., Bhat, B., Linsley, P. S., & Walter, N. G. (2012) · RNA · doi:10.1261/rna.033308.112 · Cited by 54
“2010) and lung (Hatley et al. 2010), activation of another oncogene, such as K-ras (Hatley et al.”
BackgroundInfluentialBLIMP-1 and STAT3 Counterregulate MicroRNA-21 during Plasma Cell Differentiation
Barnes, N. A., Stephenson, S., Cocco, M., Tooze, R. M., & Doody, G. M. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1101563 · Cited by 51
Redox regulation of microRNAs in cancer
Lan, J., Huang, Z., Han, J., Shao, J., & Huang, C. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.01.010 · Cited by 49
The role of dietary phytochemicals in the carcinogenesis via the modulation of miRNA expression
Samec, M., Líšková, A., Kubatka, P., Uramova, S., Žúbor, P., Samuel, S. M., Zulli, A., Péč, M. J., Bielik, T., Biringer, K., et al. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-02940-0 · Cited by 51
Control by a hair’s breadth: the role of microRNAs in the skin
Ning, M. S., & Andl, T. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1117-z · Cited by 48
“[89, 90], the absence of this tumor-associated microRNA has an impact on mice challenged with a chemical skin carcinogensis regimen.”
Aqp-1 Gene Knockout Attenuates Hypoxic Pulmonary Hypertension of Mice
Liu, M.-C., Liu, Q., Pei, Y., et al. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.311714 · Cited by 49
Gentilin, E., Uberti, E. C. D., & Zatelli, M. C. (2016) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2016.10.002 · Cited by 48
Zhong, Z., Dong, Z., Yang, L., & Gong, Z. (2012) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-012-1287-y · Cited by 48
microRNA regulation of cell viability and drug sensitivity in lung cancer
Du, L., & Pertsemlidis, A. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.697149 · Cited by 49
“Genome-wide mRNA and microRNA profiling of the NCI 60 cell-line screen and comparison of FdUMP[10] with fluorouracil, floxuridine, and topoisomerase 1 poisons.”
BackgroundBorkowski, R. J., Du, L., Zhao, Z., McMillan, E. A., Kosti, A., Yang, C., Suraokar, M. B., Wistuba, I. I., Gazdar, A. F., Minna, J. D., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1329 · Cited by 49
“miRNAs are readily manipulated both in vitro and in vivo, and both gain and loss ofmiRNA function have been demonstrated to have substantial effects on tumor initiation and progression in in vivo models (6, 13, 14).”
BackgroundNon-Coding RNAs in Lung Tumor Initiation and Progression
Santos, R. M., Moreno, C., & Zhang, W. C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082774 · Cited by 49
“miR-21 NSCLC PDCD4, APAF1 Inactivation of Tumor Suppressor I [90]”
BackgroundInfluentialThe Tumor Cytosol miRNAs, Fluid miRNAs, and Exosome miRNAs in Lung Cancer
Qin, X., Xu, H., Gong, W., & Deng, W. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2014.00357 · Cited by 47
“Since then, many miRNAs were identified as oncogenes or tumor suppressor genes, such as miR-17–92 (16, 17), miR-218 (18), miR-21 (19), and miR-34 family (miR-34a and miR-34b/c) (20–24).”
BackgroundMiR-21 is Continually Elevated Long-Term in the Brain after Exposure to Ionizing Radiation
Shi, Y., Zhang, X., Tang, X., Wang, P., Wang, H., & Wang, Y. (2011) · Radiation Research · doi:10.1667/rr2764.1 · Cited by 47
“Overexpression of miR-21 in mice results in tumorigenesis (19, 20).”
BackgroundTargeting Epigenetics in Lung CancerPreprint
Chao, Y. L., & Pecot, C. V. (2020) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a038000 · Cited by 49
Wang, W., Li, X., Liu, C., Zhang, X., Wu, Y., Diao, M., Tan, S.-Y., Huang, S., Cheng, Y., & You, T. (2022) · Bioscience Reports · doi:10.1042/bsr20211653 · Cited by 47
Liu, F., Zheng, S., Liu, T., Liu, Q., Liang, M., Li, X., Sheyhidin, I., Lu, X., & Liu, W. (2013) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-013-1693-8 · Cited by 46
Chen, C., Zhao, Z., Liu, Y., et al. (2015) · Oncology Letters · doi:10.3892/ol.2015.2873 · Cited by 46
“As a prevailing area for cancer biology studies in previous years, miRNA has been revealed to play important regulatory roles in tumorigenesis and cancer development, not only in cell proliferation and development (21-23).”
BackgroundAssociation of a peptoid ligand with the apical loop of pri-miR-21 inhibits cleavage by Drosha
Diaz, J. P., Chirayil, R., Chirayil, S., Tom, M. C., Head, K. J., & Luebke, K. J. (2014) · RNA · doi:10.1261/rna.042911.113 · Cited by 47
“Thus, genetic deletion of miR-21 in a mouse model of non–small cell lung cancer protects against tumor formation (Hatley et al. 2010), and suppression of miR-21 in tumor cells by transfection with complementary oligonucleotides results in increased apoptosis (Chan et al. 2005) or increased…”
BackgroundMicroRNA in cancer: New hopes for antineoplastic chemotherapy
Leva, G. D., Briskin, D., & Croce, C. M. (2012) · Upsala Journal of Medical Sciences · doi:10.3109/03009734.2012.660551 · Cited by 47
“Interestingly, a 4–6-fold overexpression of miR-21 resulted in no obvious phenotype; however, miR-21 overexpression potentiates the lung tumorigenesis of a constitutively activated KRAS proto-oncogene (65).”
BackgroundLi, X., Ma, J., Fang, Q., & Li, Y. (2013) · Toxicon · doi:10.1016/j.toxicon.2013.07.002 · Cited by 46
Vescovo, V. D., Meier, T., Inga, A., Denti, M. A., & Borlak, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078870 · Cited by 43
“Importantly, miR-21 over-expression is largely associated with tumor development [49] while miR-146b over-expression was reported for the human lung cancer cell line A549 [50] and in Tcells from patients with severe asthma [51].”
BackgroundSchmitz, U., Wolkenhauer, O., & Vera, J. (2013) · Advances in experimental medicine and biology · doi:10.1007/978-94-007-5590-1 · Cited by 56
MicroRNA21 and the various types of myeloid leukemia
Panagal, M., R., S. K. S., Sivakurunathan, P., Biruntha, M., Karthigeyan, M., Gopinathe, V., Sivakumare, P., & Sekar, D. (2018) · Cancer Gene Therapy · doi:10.1038/s41417-018-0025-2 · Cited by 44
miRNA-21 is developmentally regulated in mouse brain and is co-expressed with SOX2 in glioma
Põlajeva, J., Swartling, F. J., Jiang, Y., Singh, U., Pietras, K., Uhrbom, L., Westermark, B., & Roswall, P. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-378 · Cited by 45
“Furthermore, gain of function and loss of function of miR-21 in a transgenic mouse model for non-small-cell lung cancer showed that miR-21 behaved as a tumor promoter [12].”
BackgroundKang, Y.-H., Kim, D., & Jin, E. (2015) · PubMed · Cited by 44
Complex oncogene dependence in microRNA-125a–induced myeloproliferative neoplasms
Guo, S., Bai, H., Megyola, C. M., Halene, S., Krause, D. S., Scadden, D. T., & Lü, J. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1213196109 · Cited by 42
Role of Exosomal Noncoding RNAs in Lung Carcinogenesis
Sun, T., Kalionis, B., Lv, G., Xia, S., & Gao, W. (2015) · BioMed Research International · doi:10.1155/2015/125807 · Cited by 43
“Many miRNAs are oncogenes or tumor suppressor genes and these includemiR-17–92 [16, 40], miR-218 [41],miR-21 [42], andmiR-34 familymembers (miR34a and miR-34b/c) [43–47].”
BackgroundPrognostic role of microRNA-21 expression in gliomas: a meta-analysis
Li, C., Sun, J., Xiang, Q., Liang, Y., Zhao, N., Zhang, Z., Liu, Q., & Cui, Y. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2233-7 · Cited by 43
“Based on various clinical trials and in vitro studies, it has been observed that miRNA-21 is overexpressed in various human tumors and cancer cell lines including head and neck cancer, ovarian cancer, B cell lymphoma, hepatocellular carcinoma, cervical cancer and lung cancer [12, 14].”
BackgroundMelnik, B. C., John, S. M., Carrera‐Bastos, P., & Schmitz, G. (2020) · Cancers · doi:10.3390/cancers12082111 · Cited by 44
Noncoding RNAs in Regulation of Cancer Metabolic Reprogramming
Yang, D., Sun, L., Li, Z., & Gao, P. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-1498-7_7 · Cited by 42
Wang, S.-H., Xu, L., Zhou, L., et al. (2013) · Tumor Biology · doi:10.1007/s13277-013-0954-1 · Cited by 41
“miR-21 is thought to inhibit apoptosis by suppressing the inhibition of the Ras/MEK/ERK pathways [28].”
Background“Skeletal Muscle MicroRNAs: Their Diagnostic and Therapeutic Potential in Human Muscle Diseases”
Alexander, M. S., & Kunkel, L. M. (2015) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-140058 · Cited by 41
“Interestingly, miR-21 global knockout mice are viable and have reduced tumorigenic capacity in several non-muscle cell cancers due to an induction of the inhibitors of the Ras/MEK/ERK signaling pathways that normally repressed by miR-21 function [50, 51].”
BackgroundThe feedback loop between miR-21, PDCD4 and AP-1 functions as a driving force for renal fibrogenesis
Sun, Q., Miao, J., Luo, J., Yuan, Q., Cao, H., Su, W., Zhou, Y., Jiang, L., Fang, L., Dai, C., et al. (2018) · Journal of Cell Science · doi:10.1242/jcs.202317 · Cited by 41
“Micewith heterozygous or homozygousmiR-21 deletion in C57BL/6J background were fertile and appeared phenotypically normal, similar to previous reports (Hatley et al., 2010).”
ResultTang, H., Zhang, Y., Li, D., Fu, S., Tang, M., Wan, L., Chen, K., Liu, Z., Xue, L., Peng, A., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.06.048 · Cited by 44
miRNA-Directed Regulation of the Main Signaling Pathways in Thyroid Cancer
Ramírez-Moya, J., & Santisteban, P. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00430 · Cited by 42
Simultaneous downregulation of miR-21 and upregulation of miR-7 has anti-tumor efficacy
Bhere, D., Arghiani, N., Lechtich, E. R., Yao, Y., Alsaab, S. M., Bei, F., Matin, M. M., & Shah, K. (2020) · Scientific Reports · doi:10.1038/s41598-020-58072-w · Cited by 41
“Previous studies have also shown that miR-21 activates RAS/MAPK pathway through targeting antagonists of this pathway 45 and can simultaneously inhibit PI3K/AKT and RAF/MEK/ERK in GBM 46 . miR-7 is also known to induce apoptosis through inhibition of BCL2 43 and inhibition of miR-21 activates…”
MiRNA-1469 promotes lung cancer cells apoptosis through targeting STAT5a.
Xu, C., Zhang, L., Li, H., et al. (2015) · PubMed · Cited by 40
MicroRNAs in Respiratory Disease. A Clinician’s Overview
Brown, D., Rahman, M., & Nana-Sinkam, S. P. (2014) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201404-179fr · Cited by 40
Expression profile of MicroRNA: An Emerging Hallmark of Cancer
Zaheer, U., Faheem, M., Qadri, I., Begum, N., Yassine, H. M., Thani, A. A. A., & Mathew, S. (2019) · Current Pharmaceutical Design · doi:10.2174/1386207322666190325122821 · Cited by 39
The Mir181ab1 cluster promotes KRAS-driven oncogenesis and progression in lung and pancreas
Valencia, K., Erice, O., Kostyrko, K., Hausmann, S., Guruceaga, E., Tathireddy, A., Flores, N. M., Sayles, L. C., Lee, A. G., Fragoso, R., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci129012 · Cited by 39
“Previous studies have suggested upregulation and functional roles for miR21, miR450b-5p and miR30c in response to oncogenic KRAS in cancer (14-17).”
Mir-21 Suppression Promotes Mouse Hepatocarcinogenesis
de Sousa, M. C., Calo, N., Sobolewski, C., Gjorgjieva, M., Clément, S., Maeder, C., Dolicka, D., Fournier, M., Vinet, L., Montet, X., et al. (2021) · Cancers · doi:10.3390/cancers13194983 · Cited by 41
Overcoming Resistance to Endocrine Therapy in Breast Cancer: New Approaches to a Nagging Problem
Luqmani, Y. A., & Alam-Eldin, N. (2016) · Medical Principles and Practice · doi:10.1159/000444451 · Cited by 39
SONG, Q., Zhong, L., Chen, C., TANG, Z., Liu, H., Zhou, Y., Tang, M., Zhou, L., Zuo, G., Luo, J., et al. (2015) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2015.2363 · Cited by 39
“The elevated expression of miR-21 has been observed in multiple types of tumors, and the suppression of miR-21 in tumors has been shown to lead to reduced cell proliferation and migration, suggesting that miR-21 acts as an oncogene (10-19).”
Paliouras, A. R., Monteverde, T., & Garofalo, M. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.02.029 · Cited by 39
Pace, E., Vincenzo, S. D., Salvo, E. D., et al. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28786 · Cited by 39
“MiR‐21 drives tumorigenesis processes activating Ras/MEK/ERK kinase pathway through inhibition of its negative regulators (Hatley et al., 2010).”
BackgroundThe pluripotency factor NANOG promotes the formation of squamous cell carcinomas
Palla, A. R., Piazzolla, D., Alcázar, N., Cañamero, M., Graña‐Castro, O., Goméz-López, G., Domínguez, O., Dueñas, M., Paramio, J. M., & Serrano, M. (2015) · Scientific Reports · doi:10.1038/srep10205 · Cited by 40
MicroRNAs as Oncogenes and Tumor Suppressors
Rufino‐Palomares, E. E., Reyes‐Zurita, F. J., Lupiáñez, J. A., & Medina, P. P. (2013) · Wiley eBooks · doi:10.1002/9781118300312.ch14 · Cited by 43
Pass, H. I., Beer, D. G., Joseph, S. O., & Massion, P. P. (2013) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2013.01.002 · Cited by 38
“Let-7 has been linked to ras,(62) andmir-21 acts as an antiapoptotic factor and promotes cell proliferation.(63)”
BackgroundRelevance of miR-21 in HIV and non-HIV-related lymphomas
Sekar, D., Islam, V. I. H., Thirugnanasambantham, K., & Saravanan, S. (2014) · Tumor Biology · doi:10.1007/s13277-014-2068-9 · Cited by 39
He, Z., Zhang, P., Li, X., Zhang, J., & Zhu, J. (2016) · Scientific Reports · doi:10.1038/srep22737 · Cited by 38
Zennami, K., Choi, S., Liao, R. S., Li, Y., Dinalankara, W., Marchionni, L., Rafiqi, F. H., Kurozumi, A., Hatano, K., & Lupold, S. E. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0837 · Cited by 39
Gao, Z., Xu, M., Yue, S., Shan, H., Xia, J., Jiang, J., & Yang, S. (2021) · Current Research in Pharmacology and Drug Discovery · doi:10.1016/j.crphar.2021.100079 · Cited by 37
“The RAS-Raf-MEK-ERK pathway plays a vital role in tumorigenesis through small multi-faceted RNA and is the target for anti-cancer therapy (Hatley et al., 2010).”
BackgroundPAX3-FOXO1 dictates myogenic reprogramming and rhabdomyosarcoma identity in endothelial progenitors
Searcy, M. B., Larsen, R. K., Stevens, B. T., Zhang, Y., Jin, H., Drummond, C. J., Langdon, C. G., Gadek, K. E., Vuong, K., Reed, K. B., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43044-1 · Cited by 39
Self-citationHanna, J. A., Garcia, M. R., Go, J. C., Finkelstein, D., Kodali, K., Pagala, V., Wang, X., Peng, J., & Hatley, M. E. (2016) · Cell Death and Disease · doi:10.1038/cddis.2016.159 · Cited by 36
“Immunoblotting was performed on whole-cell extracts as described previously.(46) Antibodies applied overnight as detailed in Supplementary Table S3.”
MethodSelf-citationShan, X., Zhang, H., Zhang, L., Xin Min, Z. H. O. U., Wang, T., Zhang, J., Shu, Y., Zhu, W., Wen, W., & Liu, P. (2018) · Cancer Medicine · doi:10.1002/cam4.1490 · Cited by 36
“Aberrantly increased miR- 215p could promote lung tumorigenesis and inhibit cell apoptosis via the Ras/ MEK/ERK and activate EGFR signaling pathway [33, 34].”
BackgroundMultidimensional communication of microRNAs and long non-coding RNAs in lung cancer
Guo, T., Li, J., Zhang, L., Hou, W., Wang, R., Zhang, J., & Gao, P. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2767-5 · Cited by 38
Wu, C., Chen, W., Fang, M., et al. (2018) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2018.11.007 · Cited by 37
MiRNAs in Lung Cancer: Diagnostic, Prognostic, and Therapeutic Potential
Wani, J. A., Majid, S., Imtiyaz, Z., Rehman, M. U., Alsaffar, R. M., Shah, N. N., Alshehri, S., Ghoneim, M. M., & Imam, S. S. (2022) · Diagnostics · doi:10.3390/diagnostics12071610 · Cited by 39
“(Spry1, Spry2, Btg2, and Pdcd4) pathway and apoptosis (Apaf1, Faslg, RhoB, and Pdcd4) pathway [63].”
Background
Metadata
- Authors
- Hatley, M. E., Patrick, D. M., Garcia, M. R., Richardson, J. A., Bassel-Duby, R., van Rooij, E., & Olson, E. N.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- Corresponding author
- Olson, Eric N.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2010-09
- Volume
- 18
- Issue
- 3
- Pages
- 282-293
- ISSN
- 1535-6108 (ISSN-L)
- PMC
- PMC2971666
- OpenAlex
- W2169354377
- Semantic Scholar
- ea1aaa83b1883a1290ce31db3401b12568b668c7
- Cited by
- 626
- References
- 74
- Citations by year
- 2026: 12 · 2025: 15 · 2024: 26 · 2023: 22 · 2022: 38 · 2021: 31 · 2020: 28 · 2019: 29 · 2018: 42 · 2017: 31 · 2016: 40 · 2015: 72 · 2014: 57 · 2013: 62 · 2012: 63
- FWCI
- 16.52
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cancer Cell (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (submittedVersion)
- PubMed Central (submittedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R01HL093039)
- National Cancer Institute
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (K12HD000850)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- miR-21, KRAS, lung carcinogenesis, non-small cell lung cancer, Ras/MEK/ERK pathway, apoptosis inhibition, transgenic mouse model, tumor suppressor microRNA
- MeSH terms
- Animals, Carcinoma, Non-Small-Cell Lung, Cell Transformation, Neoplastic, Humans, Lung Neoplasms, Mice, Nude, Mice, Transgenic, Genes, ras, Signal Transduction, MicroRNAs, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-21, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-21 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review